Insights From: Brian Rini,MD, Cleveland Clinic Main Campus; David F. McDermott, MD, Harvard Cancer Center
RCC is the seventh leading cause of cancer deaths in the U.S. Check out this article for an overview of the condition.
There will be 65,340 new cases of kidney cancer diagnosed in 2018.
Dr. Brian Rini talks about resistance in metastatic RCC.
Artificial-Intelligence Smartphone App Significantly Reduced Severity of Cancer Patientsâ Pain and Hospital Admissions
A study of 112 people with metastatic solid tumors found that the use of an artificial intelligence (AI)-based smartphone app reduced both the severity of patientsâ reported pain and hospital admissions.
Dr. Brian Rini discusses different clinical trials for kidney cancer.
Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: A single center experience
Sunitinib treatment has acceptable efficacy and safety profile in Malaysian mRCC patients. The MSKCC and IMDC factors are relevant for predicting survival in our patient cohort while HFS is a promising prognostic predictor which warrants further investigation.
miRâ122 promotes proliferation and invasion of clear cell renal cell carcinoma by suppressing Forkhead box O3
MicroRNAs (miRNAs) serve an important role in renal cancer, but renal cancer miRNA expression data remains inconsistent.
According to Dr. Eve Glazier, the patients who responded best to treatment with a certain class of immunotherapy drugs were those with the more diverse and robust gut microbiomes.
Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma
An analysis showed that fatty acid binding protein 7 (FABP7) has the highest mean differential overexpression in ccRCC compared to normal kidney.
|NeonCRM by Neon One|